Comment on

• MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

  Fürstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, Bittenbring J, Hebart H, Schöttker B, Illert AL, Graeven U, Stoltefuß A, Heinrich B, Eckert R, Fink A, Stumpf J, Fischer K, Al-Sawaf O, Simon F, Kleinert F, Weiss J, Kreuzer KA, Schilhabel A, Brüggemann M, Langerbeins P, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P. Fürstenau M, et al. Blood. 2025 Mar 20;145(12):1282-1292. doi: 10.1182/blood.2024026685. Blood. 2025. PMID: 39883943 Clinical Trial.